180 Wealth Advisors LLC lowered its stake in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 1.1% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 32,800 shares of the biopharmaceutical company’s stock after selling 364 shares during the quarter. 180 Wealth Advisors LLC’s holdings in Pfizer were worth $1,202,000 at the end of the most recent quarter.
A number of other institutional investors also recently bought and sold shares of PFE. BlackRock Inc. increased its stake in Pfizer by 0.6% in the first quarter. BlackRock Inc. now owns 445,384,893 shares of the biopharmaceutical company’s stock worth $18,171,704,000 after purchasing an additional 2,516,132 shares during the period. Wellington Management Group LLP increased its stake in Pfizer by 9.8% in the 1st quarter. Wellington Management Group LLP now owns 218,931,933 shares of the biopharmaceutical company’s stock worth $8,932,423,000 after buying an additional 19,602,359 shares during the period. Moneta Group Investment Advisors LLC lifted its holdings in Pfizer by 89,592.7% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company’s stock valued at $8,257,000,000 after buying an additional 160,963,976 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Pfizer by 0.5% during the 1st quarter. Geode Capital Management LLC now owns 109,852,779 shares of the biopharmaceutical company’s stock valued at $4,472,433,000 after buying an additional 577,201 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its stake in Pfizer by 14.4% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 83,901,181 shares of the biopharmaceutical company’s stock worth $3,408,836,000 after acquiring an additional 10,560,702 shares in the last quarter. 68.05% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
PFE has been the subject of several research analyst reports. Morgan Stanley decreased their price target on shares of Pfizer from $42.00 to $40.00 and set an “equal weight” rating for the company in a research note on Wednesday, August 2nd. StockNews.com assumed coverage on Pfizer in a research report on Thursday, August 17th. They set a “hold” rating on the stock. Truist Financial restated a “buy” rating and issued a $62.00 price objective on shares of Pfizer in a report on Wednesday, September 13th. JPMorgan Chase & Co. dropped their target price on shares of Pfizer from $45.00 to $41.00 and set a “neutral” rating on the stock in a report on Monday, July 17th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $75.00 price target on shares of Pfizer in a research report on Monday. Twelve investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $46.35.
Pfizer Trading Down 1.3 %
Shares of Pfizer stock opened at $33.64 on Tuesday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.82 and a current ratio of 2.12. The company has a market cap of $189.93 billion, a P/E ratio of 8.95, a price-to-earnings-growth ratio of 1.14 and a beta of 0.59. The firm has a 50-day simple moving average of $35.80 and a two-hundred day simple moving average of $37.96. Pfizer Inc. has a fifty-two week low of $33.44 and a fifty-two week high of $54.93.
Pfizer (NYSE:PFE – Get Free Report) last posted its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, topping analysts’ consensus estimates of $0.57 by $0.10. Pfizer had a net margin of 27.55% and a return on equity of 28.36%. The company had revenue of $12.73 billion during the quarter, compared to analysts’ expectations of $13.36 billion. During the same period in the prior year, the business posted $2.04 earnings per share. The firm’s revenue for the quarter was down 54.1% on a year-over-year basis. As a group, equities analysts predict that Pfizer Inc. will post 3.33 earnings per share for the current fiscal year.
Pfizer Announces Dividend
The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 5th. Investors of record on Friday, July 28th were paid a $0.41 dividend. This represents a $1.64 annualized dividend and a yield of 4.88%. The ex-dividend date of this dividend was Thursday, July 27th. Pfizer’s dividend payout ratio is currently 43.62%.
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
- Five stocks we like better than Pfizer
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Nikola’s Stock Could Double in Price Within Weeks
- What are stock market earnings reports?
- Drones Can Lift AeroVironment Shares To New Heights
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- On Holding Gets Back Into the Race After Gapping Down
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.